US regulators will decide this week whether a group of popular peptides, strongly promoted by Health Secretary Robert F. Kennedy Jr, should be made available through licensed compounding pharmacies.
The Pharmacy Compounding Advisory Committee of the Food and Drug Administration (FDA) meets on Thursday and Friday to review seven peptides currently marketed for muscle growth, anti-ageing, sleep, wound healing, weight loss and other uses.
Peptides — short chains of amino acids that occur naturally in the body — have moved from niche bodybuilding and biohacking circles into mainstream wellness culture. They are widely promoted by social media influencers and the “looksmaxxing” trend.
Kennedy has publicly stated he has used certain peptides with “really good effect” and argued that current restrictions have pushed consumers into an unregulated grey market.
Among the compounds under review are BPC-157, TB-500 and KPV, which are marketed for conditions including inflammation, ulcerative colitis, chronic pain, insomnia and opioid withdrawal.
Despite soaring demand, FDA scientists have questioned the evidence supporting many of these peptides. Agency documents released ahead of the meeting state there is limited human clinical trial data on their safety and effectiveness, along with concerns about quality, stability and consistency.
Industry groups counter that allowing licensed pharmacies to compound the peptides would improve quality control and reduce risks from unregulated suppliers.
The makeup of the advisory committee has also drawn criticism. Seven of its 14 members reportedly have ties to businesses or clinics involved in peptide therapies. Some run clinics that sell peptide injections or promote them on social media.
The Department of Health and Human Services has defended the panel, saying all members underwent the required federal ethics review.
While the committee’s recommendations are not binding, they are expected to influence the FDA’s final decision on the RFK Jr peptides FDA review.